Clinical study of dexmedetomidine on deep brain stimulation in middle-aged and elderly patients with Parkinson's disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037957

Enrollment

Unknown

Registered

2020-09-07

Start date

2016-12-01

Completion date

Unknown

Last updated

2020-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep brain stimulation in patients with Parkinson's disease

Interventions

Experimental group:conscious sedation with dexmedetomidine

control group:Pump in normal saline

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Parkinson's patients with DBS indications; 2. Patients aged 45-75 years, ASA I - III; 3. Conscious patients.

Exclusion criteria

Exclusion criteria: 1. Patients with adverse reactions to anesthesia in the past; 2. Patients with contraindication of dexmedetomidine (severe sinus bradycardia and allergy); 3. Patients with contraindication of remifentanil, propofol and flurbiprofen axetil; 4. Patients with contraindication of LMA placement (chronic obstructive pulmonary disease, oropharyngeal disease); 5. Patients with dementia type PD.

Design outcomes

Primary

Measure	Time frame
blood pressure;heart rate;BIS value;Rasmay score;Propofol dosage;Remifentanil dosage;nduction time of laryngeal mask airway anesthesia;Recovery time of laryngeal mask airway anesthesia;Anesthetic concentration;UPDRS score;PDQ39 score;Serum metabonomics;The times of the METs or patient test is disturbed;PETCO2;SPO2%;	—

Secondary

Measure	Time frame
CT / MRI of target target;Operation time of the first stage;Laryngeal mask anesthesia time;Age, gender, BMI;	—

Countries

China

Contacts

Public ContactWenyi Zhang

Shanghai Tongren Hospital

273735792@qq.com+86 13688084887

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026